

1 **Feasibility of an Innovative Absorbable Ventilation Tube Designed to Provide**  
2 **Intermediate-Term Middle Ear Ventilation**

3  
4 Sandra Skovlund, MD (Corresponding Author)

5 Adjunct Faculty

6 University of Minnesota Department of Otolaryngology- Head and Neck Surgery

7 Minneapolis, MN

8 Winze003@umn.edu

9 Shelagh Cofer, MD

10 Associate Professor, Chair- Division of Pediatric Otolaryngology

11 Mayo Clinic

12 Rochester, MN

13 Cofer.shelagh@mayo.edu

14 Heather Weinreich, MD

15 Assistant Professor

16 University of Chicago

17 Hweinre1@uic.edu

18 **KEYWORDS:** feasibility, eustachian tube dysfunction, ventilation tube, absorbable,  
19 middle ear ventilation

20 **CONFLICT OF INTEREST:** SS is owner of Skovlund Medical Products, LLC

21 **AUTHOR ROLES:** SS, SC, HW contributed to study design, study execution, device  
22 evaluation, data analysis, and manuscript review. SS contributed to manuscript  
23 preparation and presentation.

24

25 **ABSTRACT**

26 Myringotomy with ventilation tube placement is a common surgical procedure performed  
27 in children and adults to remove fluid build-up behind the tympanic membrane.  
28 However, retention of tubes beyond achievement of therapeutic response increases risk  
29 for complications and additional intervention. This small feasibility study was conducted  
30 to demonstrate proof-of-concept of a novel bioabsorbable ventilation tube that provides  
31 the necessary duration of ventilation with absorption shortly thereafter in humans.  
32 Tubes were placed in 15 ears of 14 patients meeting indications for short or  
33 intermediate-duration of middle ear ventilation. Two independent examiners  
34 documented tube patency and tube absorption status at 3, 6 and 12 weeks or until  
35 absorption was complete. Results indicate that average ventilation time was 12 weeks  
36 (range 3 weeks to 18 months). There was no observation of blockage. These findings  
37 support the feasibility of a novel bioabsorbable ventilation tube.

## 38 INTRODUCTION

39 Myringotomy and ear tube placement is a common surgical procedure to remove or  
40 prevent fluid build-up behind the eardrum or to instill medication into the middle ear.  
41 Placement of ear tubes, also referred to as ventilation tubes, is the most common  
42 surgery performed in the pediatric population for repeated middle ear infections. Ear  
43 tube placement is also indicated in adults with eustachian tube dysfunction, serous otitis  
44 media(SOM), sudden sensorineural hearing loss(SSNHL) or a Meniere's  
45 exacerbation(ME). Previous reports suggest that ventilation time of 3 weeks can be  
46 sufficient to prevent recurrence of otitis media in a majority of cases.<sup>1</sup> In most cases the  
47 ventilation tube self-extrudes at 6-18 months, however complications have been  
48 reported if durable tube material(fluoroplastics, silicone, titanium) remains in place  
49 beyond 4-6 months.<sup>2,3</sup> In practice, tubes that are retained beyond two years are  
50 removed and the residual perforation is patched.

51 To address the need for an ear tube that provides intermediate-term ventilation to  
52 successfully treat several ear conditions without risks of foreign body complications, a  
53 bioabsorbable ventilation tube (BVT) has been developed. The BVT is constructed from  
54 materials commonly used in the ear that have substantial documentation of safety and  
55 bioabsorption predictability. The objective of this study was to evaluate feasibility of this  
56 novel BVT in adult patients indicated for intermediate-duration middle ear ventilation.

## 57 METHODS

58 This small feasibility study was conducted at a single multi-specialty group practice was  
59 approved by an Institutional Review Board for Human Subjects Research. **Adult**  
60 **participants** with acute SOM, SSNHL, or ME were eligible for placement of a short-

61 duration BVT tube in a clinic setting. **The BVT is composed of gelatin and a suspension**  
62 **of antibiotic and steroid that is commonly administered in the middle ear.** Patients were  
63 evaluated at weeks 3, 6, and 12 by two examiners to document time to BVT lumen  
64 patency in the process of absorption. Exam findings were verified and recorded  
65 independently by each examiner using binocular microscopy.

## 66 **RESULTS**

67 Fourteen participants, ages 26-80 years (mean age 61 years, 47% female) voluntarily  
68 underwent placement of a BVT tube in 15 ears. All patients completed the placement  
69 and absorption period without complication. Two patients were not included in the  
70 descriptive statistics for ventilation time: 1 patient (1 ear) who did not complete  
71 evaluation at the designated intervals; and 1 patient (2 ears) who received radiation  
72 following BVT placement and had an expected delay in tube absorption.

73 Average time for middle ear ventilation was 9 weeks (range 3 weeks to 12 weeks;  
74 n=12). BVTs showed progressive signs of resorption at each follow-up visit. There were  
75 no observations of BVT lumen occlusion.

## 76 **DISCUSSION**

77 This report provides feasibility for a novel bioabsorbable ventilation tube in adults who  
78 met criteria for short or intermediate-term ventilation of the middle ear. Ventilation tube  
79 placement is a common treatment for numerous ear conditions in pediatric and adult  
80 populations. In the interval between tube placement and 4-6 months, ventilation tubes  
81 are quite successful at clearing otitis media, yet ventilation tubes made with durable  
82 materials (fluoroplastics, silicon, titanium) have been shown to cause expensive  
83 complications starting at 4-6 months and following tube removal at 2 years post-

84 placement due to a higher rate of eardrum perforations.<sup>2</sup> These complications contribute  
85 to additional health care costs (\$170 - \$3000 per case) related to otorrhea, ear drum  
86 perforation, tube obstruction, granulation tissue/foreign body reaction, and segmental  
87 atrophy.<sup>2,3</sup> The adequate duration of ventilation to re-establish normal middle ear  
88 function has yet to be established, though there is evidence time to efficacy is a shorter  
89 time than duration of current durable tubes treatment. Studies have shown that  
90 ventilation of less than 4 months is adequate for treatment of recurrent otitis,<sup>1</sup> indicating  
91 the opportunity to reduce over-treating without compromise to the primary clinical  
92 outcome and with a potential benefit of reducing complications.

93 The BVT development and application presented here is aligned with medical advances  
94 focusing on minimally invasive interventions and efficient clinic utilization, including the  
95 exploration of absorbable devices to treat disease. In endoscopic sinus surgeries, drug-  
96 eluting absorbable stents have been successful in decreasing scarring and polyp  
97 recurrence in the postoperative period following sinus surgery.<sup>4</sup> Furthermore,  
98 absorbable facial plating for pediatric trauma is used to eliminate a life-long foreign  
99 body. Here the BVT is composed of materials already accepted and used by  
100 Otolaryngologists, thereby providing the surgeon predictable behavior and reassurance.  
101 Our results confirm previous reports of gelatin resorption in the ear without  
102 complication.<sup>5</sup>

### 103 **CONCLUSION**

104 Here we provide feasibility of a novel BVT that provides adequate ventilation time for  
105 potential clinical application in adult patients with assorted otological conditions. In  
106 addition to providing potential benefit for traditional indications such as otitis media, the

107 BVT may be indicated in the growing use of eustachian tube balloon dilation, hyperbaric  
108 oxygen treatments, and drug delivery to the middle ear. A clinical study will be initiated  
109 to optimize BVT utility for these conditions.

110

## 111 **ACKNOWLEDGEMENTS**

112 The authors thank Amy Moore, PhD for her review of the manuscript.

113 **REFERENCES**

114

115 1. Siegel G, Brodsky L, Waner M, Shaha S. Office-based laser assisted tympanic  
116 membrane fenestration in adults and children: pilot data to support an alternative  
117 to traditional approaches to otitis media. *Int J Pediatr Otorhinolaryngol.*  
118 2000;53(2):111-120.

119 2. Kay DJ, Nelson M, Rosenfeld RM. Meta-analysis of tympanostomy tube  
120 sequelae. *Otolaryngol Head Neck Surg.* 2001;124(4):374-380.

121 3. Knutsson J, Priwin C, Hessén-Söderman AC, Rosenblad A, von Unge M. A  
122 randomized study of four different types of tympanostomy ventilation tubes - Full-  
123 term follow-up. *Int J Pediatr Otorhinolaryngol.* 2018;107:140-144.

124 4. Minni A, Dragonetti A, Sciuto A, et al. Use of balloon catheter dilation and  
125 steroid-eluting stent in light and severe rhinosinusitis of frontal sinus: a  
126 multicenter retrospective randomized study. *Eur Rev Med Pharmacol Sci.*  
127 2018;22(21):7482-7491.

128 5. Shen Y, Teh BM, Friedland PL, Eikelboom RH, Atlas MD. To pack or not to  
129 pack? A contemporary review of middle ear packing agents. *Laryngoscope.* 2011  
130 M;121(5):1040-

